Intellia Therapeutics

US · NTLA #2899 by market cap Listed 2016

11.71 -0.66 -5.34%

Live - 5344 symbols - heartbeat 558s ago · 2026-10-08 08:18

Pre-market 11.72 +0.09%

After-hours 11.81 +0.85%

Overnight 11.68 -0.26%

Market cap: 1.64B
P/E (TTM): -3.51
P/B: 2.25
EPS: -3.81
Div yield: 0.00%
52W pos: 19%

Reader sentiment Are you bullish or bearish on NTLA?

Anonymous reader poll. Unscientific, not investment advice.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Founded: 2014
CEO: Dr. John M. Leonard, M.D.
Employees: 377
Headquarters: Cambridge, Massachusetts, United States of America
Fiscal year end: 12-31
Website: intelliatx.com

Company profile

Exchange: US
Symbol: NTLA
Market-cap rank: #2899
Listing date: 2016-05-06
Market cap: 1.64B
Float cap: 1.57B
Shares out: 140.13M
Float shares: 134.15M

Sectors & themes

Biotechnology ARK Portfolio Gene Editing Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:18:31 · For reference only, not investment advice and not tailored to your situation.